CTLA4 and cancer: MARCH1 and CD83, in addition to PD-1 and CTLA-4, are promising immune regulators that can be explored to activate host immune responses, including activation of T-helper cells and production of IFN-I that appear to be associated with successful immunotherapy for cancers [110].